Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study

Overview of attention for article published in Experimental Hematology & Oncology, November 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 2 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 5 publications that cite this research output.

5

The most recent citing publications are shown below. View all 5 publications that cite this research output on Dimensions.

Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis

Article in Cancers (February 2024)

Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis

Article in BMC Ophthalmology (November 2023)

Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: A systematic review and meta-analysis

Preprint in Research Square (May 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.